Tafasitamab (MONJUVI/MINJUVI), a CD19-targeting immunotherapy developed through a global collaboration between MorphoSys and Incyte, is an established treatment option for adult patients with relapsed/refractory DLBCL who are ineligible for autologous stem cell transplant, as well as in combination regimens for relapsed/refractory follicular lymphoma. The asset has progressed through multiple strategic partnerships, with a 2010 licensing agreement between MorphoSys and Xencor, followed by a co-commercialization agreement between MorphoSys and Incyte in the US in January 2020, and in February 2024, Incyte subsequently acquiring full global rights, consolidating worldwide development and commercialization under its leadership.

In relapsed/refractory DLBCL, tafasitamab plus lenalidomide has demonstrated durable clinical benefit in transplant-ineligible patients and is being further evaluated in the Phase III frontMIND trial. The company is planning a supplemental Biologics License Application (sBLA) submission in H1 2026.

At ASCO 2026, primary analysis data (cutoff: October 20, 2025) from the frontMIND trial were presented, in which 899 patients were randomized to receive Tafa-Len-R-CHOP (n=448) or R-CHOP (n=451).

Key Efficacy Highlights:

• Progression-Free Survival (PFS): 25% reduction in risk of progression or death with tafasitamab + lenalidomide + R-CHOP vs. R-CHOP (HR: 0.75; p = 0.019)

• 2-year PFS rate: 71.1% vs. 62.9%; 3-year PFS rate: 67.3% vs. 60.7%

• Centrally confirmed subgroup (n=773): 32% risk reduction (HR: 0.68) with improved 2-year PFS of 72.7% vs. 62.2% 

• Event-Free Survival (EFS): Improved (HR: 0.79; p = 0.026) with 2-year rates of 65.0% vs. 56.7% 

• Complete Response (CR): 65.2% in both arms

• Overall Response Rate (ORR): 80.4% vs. 76.1%

• Overall Survival (OS): Interim HR 0.85 (not statistically significant), with fewer deaths in combination arm (18% vs 21%)

Key Safety Highlights

• Grade ≥3 Treatment-Emergent Adverse Events (TEAEs): 86.7% vs. 76.1%

• Serious TEAEs: 50% vs. 39%

• Grade ≥3 hematologic toxicities: 

• Neutropenia: 69% vs. 58%

• Thrombocytopenia: 27% vs. 14%

• Anemia: 24% vs. 16%

• Fatal TEAEs: 6% vs. 4%

KOL insights

“The frontline treatment paradigm for DLBCL is entering a new era of therapeutic innovation. After decades in which R-CHOP served as the predominant standard of care, emerging regimens such as Tafa-Len-R-CHOP are expanding the range of frontline treatment options.”– Expert Opinion

“The frontMIND regimen has the potential to influence frontline treatment selection in DLBCL, particularly for patients who may have previously been considered for R-CHOP alone. The addition of tafasitamab and lenalidomide to R-CHOP could emerge as a valuable first-line treatment option for selected patient populations, supporting a more individualized approach to therapy.”– Expert Opinion 

Conclusion: 

DLBCL is the most common type of non-Hodgkin lymphoma in the United States, accounting for 32,864 cases in 2025. The DLBCL market is becoming more competitive owing to the introduction of POLIVY + R CHP in the first-line setting, and the expansion of CAR T-cell therapies in earlier lines (second-line). The space beyond the third-line plus setting has recently gained popularity as a result of the expansion of the labels of approved drugs into earlier lines. In the Phase III frontMIND study, tafasitamab in combination with lenalidomide and R-CHOP demonstrated a 25% reduction in the risk of disease progression or death vs. R-CHOP alone, with a manageable safety profile. These results underscore the potential of early CD19-directed immunotherapy to improve frontline outcomes and support the integration of targeted combination strategies into first-line DLBCL treatment paradigms.